Literature DB >> 9403714

Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.

E P Henske1, L L Wessner, J Golden, B W Scheithauer, A O Vortmeyer, Z Zhuang, A J Klein-Szanto, D J Kwiatkowski, R S Yeung.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by seizures, mental retardation, and tumors of skin, brain, heart, and kidney. In this study, we focused on two of the most frequent tumors in TSC patients, renal angiomyolipomas and subependymal giant cell astrocytomas (SEGAs). Two questions were addressed. First, is loss of tuberin, the product of the TSC2 gene, seen in both renal and central nervous system tumors from TSC patients? Second, when loss of tuberin occurs, does it affect each of the cell types seen in these tumors? We used a loss of heterozygosity approach to identify tumors from TSC2 patients. We found loss of tuberin immunostaining in the spindle and epithelioid cells but not in the giant cells of six TSC2 SEGAs. We also found loss of tuberin immunostaining in all three cell types (smooth muscle, fat, and vessels) of six TSC2 angiomyolipomas. Chromosome 16p13 loss of heterozygosity occurred in both spindle and epithelioid cells of a SEGA and in smooth muscle and fat but not the vessels of two angiomyolipomas. These results support a two-hit tumor suppressor model for the pathogenesis of SEGAs and angiomyolipomas. The vascular elements of angiomyolipomas and the giant cells of SEGAs may be reactive rather than neoplastic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403714      PMCID: PMC1858354     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues.

Authors:  M Menchine; J K Emelin; P S Mischel; T A Haag; M G Norman; S H Pepkowitz; C T Welsh; J J Townsend; H V Vinters
Journal:  Mod Pathol       Date:  1996-11       Impact factor: 7.842

2.  Report and abstracts of the Third International Workshop on Chromosome 9. Cambridge, United Kingdom, 9-11 April, 1994.

Authors:  S Povey; J Armour; P Farndon; J L Haines; M Knowles; F Olopade; A Pilz; J A White; D J Kwiatkowski
Journal:  Ann Hum Genet       Date:  1994-07       Impact factor: 1.670

3.  A PCR-based genetic linkage map of human chromosome 16.

Authors:  Y Shen; H M Kozman; A Thompson; H A Phillips; K Holman; J Nancarrow; S Lane; L Z Chen; S Apostolou; N A Doggett
Journal:  Genomics       Date:  1994-07-01       Impact factor: 5.736

4.  On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis.

Authors:  C Di Rocco; A Iannelli; E Marchese
Journal:  Pediatr Neurosurg       Date:  1995       Impact factor: 1.162

5.  Loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma.

Authors:  M Mizuguchi; M Kato; H Yamanouchi; K Ikeda; S Takashima
Journal:  Ann Neurol       Date:  1996-12       Impact factor: 10.422

6.  Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues.

Authors:  R Wienecke; J C Maize; J A Reed; J de Gunzburg; R S Yeung; J E DeClue
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis.

Authors:  C Kerfoot; R Wienecke; M Menchine; J Emelin; J C Maize; C T Welsh; M G Norman; J E DeClue; H V Vinters
Journal:  Brain Pathol       Date:  1996-10       Impact factor: 6.508

8.  Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study.

Authors:  J M Bonnin; L J Rubinstein; S C Papasozomenos; P J Marangos
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

9.  Distribution of glial fibrillary acidic protein in central nervous system lesions of tuberous sclerosis.

Authors:  K Stefansson; R Wollmann
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

10.  Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region.

Authors:  F Jin; R Wienecke; G H Xiao; J C Maize; J E DeClue; R S Yeung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  54 in total

Review 1.  Genetic interstitial lung disease.

Authors:  Megan Stuebner Devine; Christine Kim Garcia
Journal:  Clin Chest Med       Date:  2011-12-06       Impact factor: 2.878

2.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

3.  Diaschisis: An Old Concept Brought to New Life.

Authors:  R Michelle Saré
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

Review 4.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

5.  Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.

Authors:  G Rennebeck; E V Kleymenova; R Anderson; R S Yeung; K Artzt; C L Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

7.  Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Authors:  Jingxiang Huang; Shulin Wu; Chin-Lee Wu; Brendan D Manning
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

8.  The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Authors:  Elena Lesma; Silvia Maria Sirchia; Silvia Ancona; Stephana Carelli; Silvano Bosari; Filippo Ghelma; Emanuele Montanari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

9.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

10.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.